KRTX Stock Overview Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Karuna Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Karuna Therapeutics Historical stock prices Current Share Price US$329.83 52 Week High US$329.99 52 Week Low US$158.38 Beta 1.15 1 Month Change 3.64% 3 Month Change 50.58% 1 Year Change 80.73% 3 Year Change 169.65% 5 Year Change n/a Change since IPO 1,547.50%
Recent News & Updates
Karuna Therapeutics, Inc. Files Form 15 Mar 29
Karuna Therapeutics, Inc.(NasdaqGM:KRTX) dropped from NASDAQ Composite Index Mar 19 Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Karuna Therapeutics, Inc. (NasdaqGM:KRTX) from Capital International Investors, FMR LLC, The Vanguard Group, Inc., T. Rowe Price Group, Inc. (NasdaqGS:TROW) and others. Mar 18
Chief Medical Officer notifies of intention to sell stock Mar 11
Consensus revenue estimates increase by 11%, EPS downgraded Feb 29
Board Member exercised options to buy US$9.9m worth of stock. Feb 28 See more updates
Karuna Therapeutics, Inc. Files Form 15 Mar 29
Karuna Therapeutics, Inc.(NasdaqGM:KRTX) dropped from NASDAQ Composite Index Mar 19 Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Karuna Therapeutics, Inc. (NasdaqGM:KRTX) from Capital International Investors, FMR LLC, The Vanguard Group, Inc., T. Rowe Price Group, Inc. (NasdaqGS:TROW) and others. Mar 18
Chief Medical Officer notifies of intention to sell stock Mar 11
Consensus revenue estimates increase by 11%, EPS downgraded Feb 29
Board Member exercised options to buy US$9.9m worth of stock. Feb 28
Full year 2023 earnings: EPS and revenues miss analyst expectations Feb 24
Karuna Therapeutics: Getting Sold Short Feb 18
Chief Medical Officer notifies of intention to sell stock Feb 11
Price target increased by 7.2% to US$327 Jan 27
Karuna Therapeutics, Inc. Announces Resignation of Steve Paul as Chief Scientific Officer and President of Research and Development Jan 17
Chief Medical Officer notifies of intention to sell stock Jan 11
Forecast to breakeven in 2026 Dec 31
Consensus revenue estimates decrease by 23% Dec 30
Consensus revenue estimates decrease by 22% Dec 26
Price target increased by 9.9% to US$291 Dec 23 Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive merger agreement to acquire Karuna Therapeutics, Inc. (NasdaqGM:KRTX) for $12.6 billion. Dec 23
Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive merger agreement to acquire Karuna Therapeutics, Inc. (NasdaqGM:KRTX) for $12.5 billion. Dec 22
Karuna Therapeutics, Inc. Announces The Lancet Publication of Data from Phase 3 EMERGENT-2 Trial Evaluating KarXT in Schizophrenia Dec 15
New minor risk - Profitability Dec 12
Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for Karxt for the Treatment of Schizophrenia Nov 29
Karuna Therapeutics, Inc. Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia Nov 17
Chief Medical Officer notifies of intention to sell stock Nov 10
Consensus revenue estimates decrease by 55% Nov 09
New minor risk - Profitability Nov 05
Third quarter 2023 earnings released: US$3.16 loss per share (vs US$2.38 loss in 3Q 2022) Nov 03
Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2023 Neuroscience Education Institute Congress Nov 02
Karuna Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023 Oct 20
Chief Medical Officer notifies of intention to sell stock Oct 13
Karuna Therapeutics, Inc. Submits New Drug Application to U.S. Food and Drug Administration for Karxt for the Treatment of Schizophrenia Sep 29
Director exercised options and sold US$2.5m worth of stock Sep 07
New minor risk - Profitability Aug 22 Karuna Therapeutics, Inc. Announces Chief Financial Officer Changes
Director exercised options and sold US$2.6m worth of stock Aug 03
Karuna Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 23
Director notifies of intention to sell stock Jul 06
CFO & Secretary notifies of intention to sell stock May 27
Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the American Society of Clinical Psychopharmacology Annual Meeting May 23
Consensus revenue estimates increase by 20% May 11
Co-Founder & COO notifies of intention to sell stock Apr 21
Chief Medical Officer exercised options and sold US$838k worth of stock Apr 13
Independent Director exercised options and sold US$96k worth of stock Apr 06
Chief Medical Officer exercised options and sold US$920k worth of stock Mar 17
Consensus revenue estimates fall by 85% Mar 02
CFO & Secretary notifies of intention to sell stock Feb 26
Chief Medical Officer notifies of intention to sell stock Feb 13
Karuna Therapeutics Appoints William P. Kane as Chief Commercial Officer Feb 01
Independent Director exercised options and sold US$113k worth of stock Jan 06
CFO & Secretary exercised options to buy US$2.3m worth of stock. Dec 20
Chief Medical Officer exercised options and sold US$965k worth of stock Dec 14 Karuna Therapeutics, Inc. Announces Executive Changes, Effective January 3, 2023
Co-Founder & COO exercised options and sold US$168k worth of stock Dec 03
Chief Medical Officer notifies of intention to sell stock Nov 16
Consensus revenue estimates fall by 25% Nov 10
Co-Founder & COO exercised options and sold US$444k worth of stock Nov 04
Chief Medical Officer exercised options and sold US$992k worth of stock Oct 13
CFO & Secretary notifies of intention to sell stock Oct 07
CFO & Secretary recently sold US$3.4m worth of stock Oct 05
Chief Medical Officer exercised options and sold US$1.2m worth of stock Sep 13
Karuna Therapeutics: This Ship Has Sailed Sep 09
Consensus forecasts updated Aug 15
Price target increased to US$236 Aug 09
Karuna Therapeutics, Inc. Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia Aug 09
Karuna Therapeutics GAAP EPS of -$2.17 misses by $0.10, revenue of $5.28M Aug 08
High number of new directors Jul 31
Chief Medical Officer exercised options and sold US$1.9m worth of stock Jul 12
Karuna Therapeutics: Front-Running KarXT Phase 3 Jun 26
Chief Medical Officer exercised options and sold US$509k worth of stock Jun 10
Independent Director notifies of intention to sell stock Jun 03
Chief Medical Officer exercised options and sold US$475k worth of stock May 10
CFO & Secretary notifies of intention to sell stock Apr 27
High number of new directors Apr 27
CFO & Secretary exercised options and sold US$518k worth of stock Apr 22
Chief Medical Officer exercised options and sold US$936k worth of stock Apr 05
Chief Medical Officer exercised options and sold US$759k worth of stock Mar 04 Shareholder Returns KRTX US Biotechs US Market 7D 3.3% -1.8% 0.4% 1Y 80.7% -2.7% 21.5%
See full shareholder returns
Return vs Market: KRTX exceeded the US Market which returned 29.3% over the past year.
Price Volatility Is KRTX's price volatile compared to industry and market? KRTX volatility KRTX Average Weekly Movement 13.9% Biotechs Industry Average Movement 11.3% Market Average Movement 6.0% 10% most volatile stocks in US Market 18.1% 10% least volatile stocks in US Market 3.0%
Stable Share Price: KRTX's share price has been volatile over the past 3 months.
Volatility Over Time: KRTX's weekly volatility has increased from 8% to 14% over the past year.
About the Company Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder.
Show more Karuna Therapeutics, Inc. Fundamentals Summary How do Karuna Therapeutics's earnings and revenue compare to its market cap? KRTX fundamental statistics Market cap US$12.58b Earnings (TTM ) -US$433.68m Revenue (TTM ) US$654.00k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) KRTX income statement (TTM ) Revenue US$654.00k Cost of Revenue US$0 Gross Profit US$654.00k Other Expenses US$434.33m Earnings -US$433.68m
Last Reported Earnings
Dec 31, 2023
Earnings per share (EPS) -11.37 Gross Margin 100.00% Net Profit Margin -66,311.93% Debt/Equity Ratio 0%
How did KRTX perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/03/18 20:09 End of Day Share Price 2024/03/15 00:00 Earnings 2023/12/31 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Karuna Therapeutics, Inc. is covered by 19 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Caroline Palomeque Berenberg Esther Lannie Hong Berenberg Jason Matthew Gerberry BofA Global Research
Show 16 more analysts 
